Zogenix Acquires Brabant Pharma Drug Lead For Dravet Syndrome
Thieme E-Journals - Neuropediatrics / Full Text - Thieme Connect
Objective: The aim of this study is to describe the treatment pattern of Dravet syndrome (DS) patients in Germany with routine anti-epileptic drugs (AEDs) ...
US9610260B2 - Method for the treatment of Dravet Syndrome
... Zogenix International Limited Method of reduction medication in treating dravet syndrome ... Anonymous, "MacReportMedia-Brabant Pharma Reports Two-Year Follow-up ...
US10478442B2 - Method for the treatment of Dravet Syndrome
... Zogenix International Limited Method of treating selected patient population experiencing dravet syndrome ... Anonymous, "MacReportMedia-Brabant Pharma Reports ...
Zogenix - Recent News & Activity - Crunchbase
PR Newswire — UCB Completes Acquisition of Zogenix, Inc. News• Feb 28 ... Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome. News• Oct 11, 2019.
Top Dravet syndrome companies | VentureRadar
... treatment for a devastating form of pediatric epilepsy called Dravet syndrome. ... Brabant Pharma. Company icon Privately Held ... Zogenix' lead product, needle ...
$130m deal for early-stage pharma firm Brabant | TheBusinessDesk ...
... drug designation in Europe and the US for the treatment of Dravet syndrome. Children with Dravet syndrome, also known as Severe Myoclonic Epilepsy of ...
Zogenix Inc (ZGNX) Q4 2018 Earnings Conference Call Transcript ...
... lead product candidate ZX008 or Fintepla for the treatment of seizures associated with Dravet syndrome in patients aged two years and older. Dravet Syndrome ...